Science Explorer Back to mapMap

Most cited papers from PreludeDx (United States)

What are the most cited papers from PreludeDx (United States)?

The most cited paper from PreludeDx (United States) is "A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk" (Troy M. Bremer, Pat W. Whitworth, Rakesh P. Patel et al., 2018), with 128 citations. Next come "The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery" (58) and "Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)" (55).

Showing 39 of 39 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk Troy M. Bremer, Pat W. Whitworth, Rakesh P. Patel et al. · Clinical Cancer Research 27 Jul 2018 128
2 The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery Chirag Shah et al. · Annals of Surgical Oncology Open access 5 Apr 2021 58
3 Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS) Fredrik Wärnberg, Per Karlsson, Erik C. Holmberg et al. · Cancers Open access 3 Dec 2021 55
4 A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy Frank A. Vicini, G. Bruce Mann, Chirag Shah et al. · International Journal of Radiation Oncology*Biology*Physics Open access 15 Sep 2022 36
5 Quantitative comparison of immunohistochemical HER2 ‐low detection in an interlaboratory study Maaike Anna Hempenius, Maran A Eenkhoorn, Henrik Høeg et al. · Histopathology Open access 29 Jul 2024 28
6 A Consortium for Analytic Standardization in Immunohistochemistry Steven A. Bogen, David J. Dabbs, Keith D. Miller et al. · Archives of Pathology & Laboratory Medicine Open access May 2022 25
7 Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial Aglaia Schiza, Viktoria Thurfjell, Axel Stenmark Tullberg et al. · European Journal of Cancer Open access 27 Feb 2022 24
8 The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT® PREDICT Study Chirag Shah et al. · Annals of Surgical Oncology Open access 25 Jun 2024 21
9 PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers Michael W Hulse et al. · Cancer Research 24 Sep 2025 20
10 High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial Carina Strell, Dick Folkvaljon, Erik C. Holmberg et al. · Clinical Cancer Research Open access 5 May 2021 16
11 Avoiding “False Positive” and “False Negative” Immunohistochemical Results in Breast Pathology Zaibo Li, David J. Dabbs · Pathobiology Open access 2022 14
12 The Story of the Magee Equations: The Ultimate in Applied Immunohistochemistry Rohit Bhargava, David J. Dabbs · Applied immunohistochemistry & molecular morphology Open access 21 Sep 2022 12
13 Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ David J. Dabbs, Karuna Mittal, SCOTT HEINEMAN et al. · Frontiers in Oncology Open access 19 May 2023 11
14 Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence Rates Frank A. Vicini et al. · International Journal of Radiation Oncology*Biology*Physics Open access 18 Jul 2025 5
15 Lack of Standardization in the Diagnosis of Invasive Lobular Carcinoma of the Breast Benjamin C. Calhoun, David J. Dabbs · Modern Pathology Open access 2023 5
16 In Support of Magnani and Taylor David J. Dabbs, Luis A. Chiriboga, Bharat Jasani et al. · Archives of Pathology & Laboratory Medicine Open access 29 Dec 2023 4
17 A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy Frank A. Vicini, Chirag S. Shah, Karuna Mittal et al. · Clinical Breast Cancer Open access 4 Sep 2024 2
18 Novel markers in breast pathology David J. Dabbs, Richard S.P. Huang, Jeffrey S. Ross · Histopathology 5 Dec 2022 2
19 Re-Thinking Clinicopathologic Risk Assessment in DCIS: Pooled Data from Validation Studies Comparing a 7-gene DCIS Assay to Clinicopathologic Features Alone Chintan Shah, F.A. Vicini, F. Wärnberg et al. · International Journal of Radiation Oncology*Biology*Physics 22 Oct 2022 2
20 CLO25-061: 7-Gene Biosignature Reclassified Women With DCIS Meeting NCCN Guideline (RTOG 9804-Like) Low-Risk Criteria as Molecular High Risk Chirag S. Shah, Frank A. Vicini, Eileen P. Connolly et al. · Journal of the National Comprehensive Cancer Network 28 Mar 2025 1
21 Biosignatures to Optimize Adjuvant Radiation Therapy Use in Patients With DCIS With High Risk Clinicopathologic Features Frank A. Vicini, Chirag Shah, Pat W. Whitworth et al. · International Journal of Radiation Oncology*Biology*Physics Open access 25 Oct 2021 1
22 The challenge of plurality. A comment on the occasion of the journal L1-Educational Studies in Language and Literature being 20 Irene Pieper · L1 Educational Studies in Language and Literature Open access Aug 2021 1
23 Periductal myxoid stroma identifies ductal carcinoma in situ at risk of invasive recurrence Aglaia Schiza, Viktoria Thurfjell, Erik Holmberg et al. · JNCI Journal of the National Cancer Institute Open access 21 Aug 2026 0
24 Beyond Fluent Replies: Evaluating Prelude as a Conversation Decision System for Emotionally Loaded Romantic Conversations Mariia Yakovleva · Zenodo (CERN European Organization for Nuclear Research) PreprintOpen access May 2026 0
25 Patterns of practice following treatment recommendation for patients with ductal carcinoma in situ using a 7-Gene predictive biosignature: Analysis of the Australian Predict Registry Y. Zissiadis, K. rahim, K. Taylor et al. · European Journal of Cancer Mar 2026 0
26 Additional file 1 of Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients Troy M. Bremer et al. · Figshare Open access 18 Feb 2026 0
27 Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients Troy M. Bremer et al. · Breast Cancer Research Open access 18 Feb 2026 0
28 The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients with Ductal Carcinoma In Situ R.A. Rabinovitch, Pat W. Whitworth, Patrick Ivan Borgen et al. · International Journal of Radiation Oncology*Biology*Physics Open access Sep 2025 0
29 Novel multi-omic biosignature for identification of early-stage invasive breast cancer patients who do and do not benefit from adjuvant radiation treatment after breast conservation surgery. Troy M. Bremer, Karuna Mittal, Chirag S. Shah et al. · Journal of Clinical Oncology 28 May 2025 0
30 TIP25-242: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients With Ductal Carcinoma In Situ Rachel A Rabinovitch, Pat W. Whitworth, Patrick Ivan Borgen et al. · Journal of the National Comprehensive Cancer Network 28 Mar 2025 0
31 ASO Visual Abstract: The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT® PREDICT Study Chirag Shah et al. · Annals of Surgical Oncology Open access 15 Jul 2024 0
32 Changes in treatment recommendations for patients with ductal carcinoma in situ using a 7-gene predictive biosignature: Analysis of the Australian PREDICT registry Yvonne Zissiadis, K. Kirkham, Amy C. Driver et al. · European Journal of Cancer Open access Mar 2024 0
33 Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence (IBR) Rates Frank A. Vicini, Chirag Shah, J. Margenthaler et al. · International Journal of Radiation Oncology*Biology*Physics Open access 29 Sep 2023 0
34 Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma In Situ Using the 7Gene Biosignature: Analysis of the PREDICT Study Chirag Shah, Pat W. Whitworth, Steven C. Shivers et al. · International Journal of Radiation Oncology*Biology*Physics Open access 29 Sep 2023 0
35 A Biosignature Integrating Immune and Metabolic Signaling Axes to Assess Limited Radiation Therapy Response in Early-Stage Breast Cancer from a Low-Risk Cohort Troy M. Bremer, Karuna Mittal, F. Wärnberg et al. · International Journal of Radiation Oncology*Biology*Physics Open access 29 Sep 2023 0
36 In Regard to Woodward and Mitchell Frank A. Vicini, Troy M. Bremer, Chirag Shah · International Journal of Radiation Oncology*Biology*Physics 22 Jun 2023 0
37 The PREDICT Registry Australia: A Prospective Registry to Evaluate the Clinical Utility of a Biomarker Assay on Treatment Decisions in Patients with DCIS Following Breast Conserving Surgery Yvonne Zissiadis, G.B. Mann, D. Speakman et al. · International Journal of Radiation Oncology*Biology*Physics 22 Oct 2022 0
38 A Novel Biosignature to Assess Residual Risk in Early Stage Invasive Breast Cancer after Standard Breast Conserving Surgery Troy M. Bremer, Christy Kesslering, Rakesh R. Patel et al. · International Journal of Radiation Oncology*Biology*Physics Open access 23 Oct 2020 0
39 Age and Grade as a Function of Decision Score in Women Diagnosed with DCIS Troy M. Bremer, Steven C. Shivers, Christy Kesslering et al. · International Journal of Radiation Oncology*Biology*Physics 23 Oct 2020 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.